Servier

What Servier does

Servier is an independent French international pharmaceutical group founded in 1954 and governed by the non-profit Fondation Internationale de Recherche Servier (FIRS), headquartered in Suresnes, France, with 10,000+ employees and operations spanning oncology, cardiometabolism, and neurology. Its commercial portfolio includes FDA-approved targeted oncology therapies VORANIGO (vorasidenib) for Grade 2 IDH-mutant glioma and OJEMDA (tovorafenib) for pediatric low-grade glioma (acquired with Day One Biopharmaceuticals in 2026), the long-established Daflon franchise for venous insufficiency, and a cardiometabolic book across cardiovascular and metabolic diseases. The R&D platform spans a 1,200-person Paris-Saclay Institute, ASO technology for rare neurological diseases, antibody-drug conjugates (Emi-Le), and AI-augmented discovery via Iktos and Insilico Medicine, with over 70% of R&D budget allocated to oncology.

Servier generates revenue primarily through prescription pharmaceutical product sales across direct country subsidiaries in France, the United States, China, India, Mexico, Egypt, Spain, Romania, and additional markets, supplemented by milestone payments and royalties from licensing arrangements such as the IDEAYA partnership for darovasertib ($210M upfront plus up to $320M in milestones). Distribution combines direct field sales forces targeting oncologists, neurologists, and cardiometabolic specialists with hospital and pharmacy channels subject to national reimbursement frameworks, plus an export-oriented single-pill-combinations manufacturing platform (GATINN) in India serving Latin America, Asia, and Africa. The company has publicly committed to €10 billion in annual revenue by 2030, with €4 billion targeted from oncology, supported by a €200M corporate venture fund (Servier Ventures) and active M&A including the 2026 Edgewise Therapeutics muscular dystrophy acquisition for up to $2.65 billion.

Name

Servier

Legal name

Les Laboratoires Servier

Website

https://servier.com

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Servier is an independent French pharmaceutical group governed by a non-profit foundation, developing and commercializing oncology, cardiometabolism, and neurology therapies including VORANIGO, OJEMDA, and Daflon for global healthcare providers and patients across rare and chronic diseases.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Oncology pharmaceuticals
• Cardiometabolic drugs
• Targeted cancer therapies
• Rare disease treatments
• Prescription medications

Headquarters

HQ city

Suresnes

HQ country

France

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Servier generates revenue from sales of prescription pharmaceutical products across its three therapeutic areas: oncology, cardiometabolism, and neurology. Key products include VORANIGO (vorasidenib), OJEMDA (tovorafenib), and Daflon. The company targets €10 billion in annual revenue by 2030, with €4 billion targeted from oncology.
2. Milestone Payments from Partnerships: Servier receives milestone payments from licensing and partnership agreements, such as the darovasertib partnership with IDEAYA (up to $320M remaining milestones) and development milestones from the Insilico Medicine AI partnership.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Servier is an independent international pharmaceutical company that develops, manufactures, and commercializes prescription drugs across three therapeutic areas: oncology (targeted therapies for rare cancers including glioma, melanoma, and solid tumors), cardiometabolism (vasoprotective and metabolic disease treatments such as Daflon for venous insufficiency), and neurology (antisense oligonucleotide therapies for rare neurodevelopmental disorders). The company invests over 20% of brand-name revenue in R&D, with more than 70% of that budget directed to oncology, and generates revenue through direct pharmaceutical product sales and partnership milestone payments.

Product overview

Servier is an independent international pharmaceutical group with three strategic therapeutic areas: Oncology (targeted cancer therapies), Cardiometabolism (cardiovascular and metabolic diseases, venous diseases), and Neurology (rare neurological diseases). The company's oncology portfolio centers on targeted therapies for rare cancers, including VORANIGO® (vorasidenib) for IDH-mutant glioma and OJEMDA (tovorafenib) for pediatric low-grade glioma following the $2.5B acquisition of Day One Biopharmaceuticals. The pipeline includes darovasertib for metastatic uveal melanoma (in partnership with IDEAYA), Emi-Le for adenoid cystic carcinoma, and sevasemten for muscular dystrophies (from Edgewise acquisition). In cardiometabolism, Servier offers Daflon® and other vasoprotective medications. The company allocates over 70% of its R&D budget to oncology and maintains partnerships with AI companies like Insilico Medicine and Iktos for drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• VORANIGO (vorasidenib): Treatment for Grade 2 IDH-mutant glioma
• OJEMDA (tovorafenib)
• Daflon
• Servier Ventures
• GATINN
• SHINEDocs
• THRPTX Innovation Summit

Products and services

• VORANIGO (vorasidenib) IDH1 inhibitor approved for treating Grade 2 IDH-mutant glioma in patients aged 12 and older. Demonstrated 44.1 months median progression-free survival in Phase 3 INDIGO trial and is the first approved targeted therapy for this indication.
• OJEMDA (tovorafenib) Type 2 RAF inhibitor FDA-approved for recurrent or refractory pediatric low-grade glioma in patients aged 6 months and older. Generated $155.4 million in 2025 sales with 172% year-over-year growth. It is the only FDA-approved monotherapy for pediatric low-grade glioma.
• TIBSOVO (ivosidenib) IDH1 inhibitor being evaluated in Phase III trial for IDH1-mutant chondrosarcoma, representing a significant unmet medical need as no approved therapy specifically for chondrosarcoma currently exists.
• Darovasertib Protein kinase C inhibitor being developed in combination with crizotinib for metastatic uveal melanoma. Phase 2/3 registrational trial showed 6.9-month median PFS vs 3.1 months for standard therapy, representing a 58% risk reduction. NDA under FDA review under the RTOR program.
• Emi-Le (Emiltatug Ledadotin) B7-H4-directed antibody-drug conjugate being developed for adenoid cystic carcinoma. Phase 1 data showed 35.6% objective response rate and 82.2% disease control rate. Received FDA Breakthrough Designation, highlighting an unmet medical need as no approved systemic therapies currently exist for advanced or metastatic ACC.
• Sevasemten First-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies. Acquired from Edgewise Therapeutics' muscular dystrophy business. Currently in pivotal Phase 3 for BMD and Phase 2 for DMD.
• Daflon 1000mg Extended-dose formulation of flavonoid-based vasoprotective medication for treating venous insufficiency and acute hemorrhoidal attacks. Launched in Italy with new 1000mg dosage for chronic venous disease.

Quantifiable outcome

• OJEMDA achieved €135M revenue in first full year with 172% growth
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core.

• n-Lorem FoundationcoreStrategic or Co-development Partner · 10 June 2026Multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches for rare neurodevelopmental disorders. n-Lorem provides ASO technology platform while Servier advances candidates into clinical development, supporting Servier's 2030 ambition for rare neurological diseases.
• Edgewise TherapeuticscoreStrategic or Co-development Partner · 1 June 2026Servier agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion ($1.55B upfront + $1.1B milestones). The acquisition includes sevasemten, an investigational treatment for Becker and Duchenne muscular dystrophies in pivotal/Phase 2 trials, positioning Servier as a global player in neuromuscular disorders.
• Day One BiopharmaceuticalscoreStrategic or Co-development Partner · 23 April 2026Servier completed acquisition of Day One Biopharmaceuticals for $2.5 billion, adding OJEMDA (tovorafenib), an FDA-approved treatment for pediatric low-grade glioma, and clinical-stage oncology pipeline assets. Day One is now part of Servier Group, strengthening Servier's rare oncology portfolio and pediatric oncology presence in the US.
• IktoscoreTechnology or Integration · 9 January 2026Multi-year AI drug discovery partnership with potential deal value exceeding €1 billion. Iktos applies its generative AI and AI-orchestrated robotics platform to design and optimize small-molecule therapeutics for undisclosed oncology and neurology targets. Servier evaluates compounds and handles preclinical/clinical development.
• Insilico MedicinecoreTechnology or Integration · 4 January 2026Multi-year AI oncology drug discovery partnership worth up to $888 million. Insilico uses its Pharma.AI platform to identify and design drug candidates while Servier leads preclinical and clinical development, regulatory activities, and global commercialization.
• IDEAYA BiosciencescoreStrategic or Co-development Partner · 2 September 2025Partnership for darovasertib (protein kinase C inhibitor) in metastatic uveal melanoma. Servier paid $210 million upfront for ex-U.S. rights with up to $320 million in potential milestone payments. Phase 2/3 trial showed 58% risk reduction in disease progression with NDA under FDA review.
• CellectiscoreStrategic or Co-development PartnerServier holds sublicense rights to Cellectis' UCART19 platform technology underlying cema-cel (allogeneic CAR-T therapy). Cellectis is eligible for up to $340 million in development and sales milestones plus double-digit royalties on net sales.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Novartis: Major Swiss pharma with deep oncology, cardiometabolic, and neurology pipelines. Comparable in three therapeutic pillars and in targeted-therapy leadership, including radioligand and rare-disease oncology.
• Sanofi: Another French-headquartered global pharma with major oncology, rare-disease, and cardiometabolic franchises. Comparable in geographic footprint, therapeutic-area mix, and French foundation/legacy ownership culture, though much larger and publicly listed.
• Takeda Pharmaceutical: Global Japanese-headquartered pharma with rare-disease, oncology, and neurology focus post-Shire acquisition. Comparable in rare-disease strategy and global M&A-driven expansion model.
• Bayer (Pharmaceuticals Division): Large diversified pharma with significant cardiometabolic and oncology franchises. Comparable in therapeutic mix (especially cardiology and oncology) and global footprint, though part of a much larger agrochemical/consumer conglomerate.
• Roche: Global oncology leader with companion diagnostics and targeted therapies directly overlapping Servier's oncology focus. Significantly larger scale and capability, but a key competitor for IDH- and glioma-related indications.

Direct peers

• UCB: Belgian specialty pharma with strong neurology (epilepsy, rare neurodevelopmental disorders) and immunology franchises. Directly comparable in neurology/rare-disease strategy and ASO-adjacent precision-medicine approach.
• Pierre Fabre: Privately-held French pharma with oncology, dermatology, and consumer health care. Overlaps with Servier in oncology focus and French private-ownership structure, though smaller and more consumer-leaning.
• Jazz Pharmaceuticals: Specialty pharma focused on rare oncology and neurology, with a track record of acquiring late-stage assets to drive growth. Comparable business model of targeting high-unmet-need rare diseases with premium pricing.
• Ipsen: French specialty pharma with a strong oncology and rare-disease focus, plus neurology (including movement disorders). Closely comparable therapeutic mix, mid-cap scale, and European origin make it Servier's most direct domestic peer.
• Recordati: European specialty pharma with rare-disease and specialty-care focus. Comparable in mid-cap specialty pharma positioning, European private/family-controlled heritage, and selective M&A growth strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/servier
• Facebookfacebook.com/servierinternational
• LinkedInlinkedin.com/company/servier
• Instagraminstagram.com/servier_group

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier